FREE ACCESS
5,000–10,000 jobs/day
See all jobs on JobTailor
Search thousands of fresh jobs every day.
Discover
- Fresh listings
- Fast filters
- No subscription required
Create a free account and start exploring right away.

Director, Global Market Access – Health Economics
PhagenesisDirector responsible for global market access strategy and health economics for Phagenesis Ltd. Collaborating on reimbursement processes across the US, EU, UK, and Ireland markets.
Core Competencies
Role fitCore Competencies
Use this summary to align your resume positioning with the role.
Demonstrates extensive experience in market access and health economics, with a strong foundation in US CMS billing and coding infrastructure. Capable of developing and executing comprehensive reimbursement strategies while effectively communicating complex concepts to diverse stakeholders.
Highest-signal resume keywords
Market Access Strategy DevelopmentUS CMS Billing and Coding ExpertiseHealth Economics and Budget Impact ModelingReimbursement Experience in Medical DevicesStakeholder Engagement and Communication
ATS Keywords
Tailor your resumeApplicant Tracking System Keywords
Tip: use these terms in your resume and cover letter to boost ATS matches.
Hard Skills
Market Access StrategyHealth EconomicsReimbursement Roadmap DevelopmentBudget Impact ModelingICD-10/CPT Code StrategyDRG Payment LogicNTAP MechanicsCrosswalk AnalysisCoverage Expansion Evidence BuildingRegulatory Navigation
Soft Skills
Exceptional Written CommunicationVerbal Communication SkillsAbility to Manage AmbiguityPrioritization SkillsCollaboration with Sales Teams
Industry Keywords
Medical DevicesPharmaceuticalBiotechnologyCMS SubmissionsIPPS RulemakingNTAP Billing PracticesDACH MarketNHS EnglandHSEMulti-Stakeholder Environments
About the role
Key responsibilities & impact- Build the strategy, infrastructure, and institutional relationships from the ground up across four markets: the United States, DACH, United Kingdom, and Ireland.
- Lead the development of the US reimbursement roadmap.
- Partner with CMRA to synthesise clinical evidence, economic data, and crosswalk analysis in support of CMS submissions and advocacy.
- Drive account-level adherence to correct NTAP billing practices.
- Monitor IPPS rulemaking cycles and MedPAC activity; develop proactive positioning and response strategies.
- Develop and execute market access strategies for the EU, UK (NHS England), and Ireland (HSE).
- Identify reimbursement barriers and accelerants at country level; build and maintain a clear market access roadmap for each region.
- Build the company’s global health economic value proposition from the ground up.
Requirements
What you’ll need- 8+ years of market access, health economics, or reimbursement experience in medical devices, pharmaceutical, or biotechnology.
- Deep, demonstrable fluency in US CMS billing and coding infrastructure — including DRG payment logic, IPPS rulemaking, NTAP mechanics, and ICD-10/CPT code strategy.
- Proven experience building the evidentiary and financial case for coverage expansion or new payment recognition with CMS.
- Ability to navigate complex, multi-stakeholder regulatory and payer environments independently.
- Strong health economics foundation — able to build and present budget impact models and value dossiers credibly to payer and C-suite audiences.
- Experience working closely with field sales teams as a reimbursement resource and commercial partner.
- Exceptional written and verbal communication skills; capable of translating complex reimbursement concepts for clinical, administrative, and executive audiences.
- Comfort operating in a start-up or commercial-stage environment — building from scratch, managing ambiguity, and prioritising across competing demands.
Benefits
Comp & perks- At Phagenesis, we are committed to transforming lives by eliminating the burden of neurogenic dysphagia.
- We put patients first, operate with courage and trust, and foster a culture that values innovation, accountability, and a challenger mindset.
- Willingness to travel up to 40%, including domestic field travel and periodic international travel to EU/UK markets.